CORPORATE INFORMATION
Growth Initiatives,
Team and Progress
CORPORATE INFORMATION
Chairman and Managing Director
(M. Pharm, Ph.D.)
Dr. Anwar S. Daud is an M. Pharm and Ph.D in pharmaceutical chemistry and pharmaceutics respectively. He began his professional journey in 1981, and returned in 1989 to Nagpur, his home town to fulfill his dream of turning entrepreneur by co-founding ZIM Laboratories.
Dr. Anwar S. Daud has been responsible for the overall growth of ZIM into an R&D based pharmaceutical manufacturing company that supplies medicines to more than 50 countries worldwide adhering to the strictest standards of quality.His keen interest in research and innovation has led ZIM to develop several innovative process technologies for manufacturing novel delivery systems and differentiated products.
He is associated with several professional bodies and continuously works for raising the standards of the pharmaceutical profession in India. He has been felicitated time and again, by various organizations for his contributions towards industry and society.
Director - Finance
A chartered accountant, Zulfiquar Kamal has been associated with the company for over 25 years. He has been on the Board of Directors since 1991. With his financial acumen, refined over an experience of more than three decades, he brings to the table the financial discipline and control necessary for a growing organization like ZIM Labs. In his current role as Director – Finance, Mr. Kamal oversees the commercial operations of the company. He envisions ZIM Labs to be a financially efficient organization known for its operational efficiencies and technological process.
Director - Business Development
Mr. Niraj Dhadiwal is a pharmacy graduate with a diploma in business management and has been with the company for nearly three decades. He started his career with ZIM Labs as a production officer in 1991, rising through ranks to his current position of Director. With his keen business acumen and technical knowledge, Mr. Dhadiwal has played a key role in the export-development arm of the company. His contribution to the development of overseas business stands unmatched and a testament to his foresight and ability to tap into new markets. In his current role as Director – Business Development, Mr. Dhadiwal looks after the business development and marketing functions of the company. He envisions ZIM Labs to have a global presence with innovative and differentiated products leading to good returns for all the stakeholders.
Director - Operations
Mr. Prakash Sapkal is a Pharmacy graduate with post-graduation in Business Administration. He is associated with the Company for 26 years starting his career as Assistant Chemist. During all these years he has handled key operations in various capacities like Production Supervisor, Production Manager, and Vice President – Operations. His major contribution has been in assembling a team that has brought the vision of ZIM Labs to life.
Independent Director
Kavita Loya is a Senior Practicing Chartered Accountant with 20 years of experience. She is on the Board as an Independent Director. She is presently a Partner in Loya Bagri & Company, Chartered Accountants. She is a Member of Capacity Building Committee of the Western Region of ICAI, Mumbai & Women’s Empowerment Committee, Nagpur Chapter.
Independent Director
A decorated IPS officer from Maharashtra with 37 years of experience, Suprakash Chakravarty is on the Board as an Independent Director. He retired as Director General – Anti Corruption Bureau, MS.
Independent Director
Dr. Gaikwad has a Doctorate in medical sciences and has over 42 years of experience in pharmaceutical sciences. He is on the Board as an Independent Director. He retired as head of the Pharmaceutical Sciences department of Nagpur University.
Independent Director
Padmakar Joshi is a senior banking professional with more than 37 years of rich and multi-functional experience in areas of commercial banking. He is on the Board as an Independent Director. He retired as Dy. Head- Corporate & SME Credit Monitoring and Debt Restructuring, Union Bank of India.
Independent Director
With a doctorate in pharmaceutical chemistry and over 40 years of experience in academics, Dr. Parashar is on the Board of Directors as an Independent Director. He is now retired from academics.
Senior Vice President – Operations
Mr.Pradeep Kataria is a postgraduate in pharmacy with an association of more than 26 years with the organization. Mr.Kataria joined ZIM as Production Supervisor in 1995.
He has been a hands-on leader of the Operations team and has been involved in successful scale-ups of pellets and taste-masking technologies developed by the company . He has also been a meticulous administrator in developing, maintaining and managing in accordance with the high standards required for various accreditations.In his current role, Mr Kataria, with his problem-solving and administration skills, looks after day-to-day activities of the plant, including manufacturing, external audits and internal coordination amongst operational departments.
Chief Financial Officer – Accounts and Finance
Mr.Patro is the CFO of ZIM and has been with the Company since April 2019.He is a Qualified Cost Accountant and Company Secretary.
He has also completed M.Sc. in Applied Mathematics form NIT Rourkela and EPBM from IIM Kolkata. He has over 23 years of experience in diversified areas covering finance, taxation, legal, commercial and control functions and is responsible for these functions in Zim Laboratories.
Senior Vice President – Technical Services
Mr.Vijay Fudke is a pharmacy graduate with an association of more than 25 years with ZIM. Having spent his initial years in the field of quality control, Mr.Fudke joined ZIM as a Quality Assurance (QA) Officer in 1996.
He has played an instrumental role in the achievement of various accreditations by the company, such as the EU-GMP, WHO-GMP & ISO 9001:2008. In his current role as Senior Vice President – Technical Services, Mr.Fudke is involved in providing clients with technical services like molecule selection for development, business expansion and high-level technical query resolution.
Focused marketing efforts on direct exports of PFI
Formulation Products
Reduction of low margin deemed exports business-particularly from Africa
Direct bidding for higher margin products
Government tenders vs. bidding through third parties
‘Commercialization’ of the OTF range of products
| Particular | FY 2020 | FY 2021 | ||||||
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| Income from Operations | 652 | 621 | 681 | 624 | 654 | 818 | 701 | 710 |
| Other Operating Income | 17 | 52 | 41 | 55 | 44 | 46 | 41 | 22 |
| Total Income from Operations | 669 | 673 | 722 | 679 | 698 | 864 | 742 | 732 |
| Operating Cost | 631 | 625 | 647 | 596 | 594 | 751 | 660 | 638 |
| EBIDTA | 38 | 48 | 75 | 83 | 104 | 113 | 82 | 94 |
| EBIT | 7 | 17 | 40 | 47 | 68 | 78 | 45 | 55 |
| Finance costs | 32 | 32 | 32 | 30 | 29 | 27 | 23 | 30 |
| Profit/(Loss) before exceptional item & tax | (25) | (15) | 8 | 17 | 39 | 51 | 22 | 25 |
| Exceptional Item | - | - | - | - | - | 52 | - | - |
| Profit/(Loss) before tax | (25) | (15) | 8 | 17 | 39 | (1) | 22 | 25 |
INR in Millions
| Particular | FY 2018 | FY 2019 | FY 2020 | FY 2021 | ||||
| H1 | H2 | H1 | H2 | H1 | H2 | H1 | H2 | |
| Income from Operations | 1,234 | 1,416 | 1,373 | 1,854 | 1,273 | 1,305 | 1,472 | 1,411 |
| Other Operating Income | 29 | 41 | 37 | 53 | 69 | 96 | 90 | 63 |
| Total Income from Operations | 1,263 | 1,457 | 1,410 | 1,907 | 1,342 | 1,401 | 1,562 | 1,474 |
| Operating Cost | 1,099 | 1,247 | 1,227 | 1,645 | 1,256 | 1,243 | 1,345 | 1,298 |
| EBIDTA | 164 | 210 | 183 | 262 | 86 | 158 | 217 | 176 |
| EBIT | 117 | 159 | 128 | 205 | 24 | 87 | 146 | 100 |
| Finance costs | 49 | 45 | 55 | 50 | 64 | 62 | 56 | 53 |
| Profit/(Loss) before exceptional item & tax | 68 | 114 | 73 | 155 | (40) | 25 | 90 | 47 |
| Exceptional Item | - | (59) | - | - | - | - | 52 | - |
| Profit/(Loss) before tax | 68 | 173 | 73 | 155 | (40) | 25 | 38 | 47 |
INR in Millions
| Particular | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
| Income from Operations | 2,650 | 3,227 | 2,578 | 2,883 |
| Other Operating Income | 70 | 90 | 165 | 153 |
| Total Income from Operations | 2,720 | 3,317 | 2,743 | 3,036 |
| Operating Cost | 2,346 | 2,872 | 2,499 | 2,643 |
| EBIDTA | 374 | 445 | 244 | 393 |
| EBIT | 276 | 333 | 111 | 246 |
| Finance costs | 94 | 105 | 126 | 109 |
| Profit/(Loss) before exceptional item & tax | 182 | 228 | (15) | 137 |
| Exceptional Item | (59) | - | - | 52 |
| Profit/(Loss) before tax | 241 | 228.00 | (15) | 85 |
INR in Millions
| Particular | FY 2018 | FY 2019 | FY 2020 | FY 2021 | ||||
| H1 | H2 | H1 | H2 | H1 | H2 | H1 | H2 | |
| Property, plant and equipment including Capital work-in-progress | 936 | 977 | 1,079 | 1,072 | 1,114 | 1,122 | 1,079 | 1,052 |
| Intangible assets including Intangible assets under development | 27 | 47 | 61 | 69 | 79 | 87 | 83 | 84 |
| Other Non-Current Assets | 135 | 229 | 121 | 195 | 256 | 257 | 255 | 237 |
| Current Assets | 1,870 | 1,721 | 1,941 | 1,912 | 1,927 | 1,763 | 1,806 | 1,830 |
| Total assets | 2,968 | 2,974 | 3,202 | 3,248 | 3,376 | 3,229 | 3,223 | 3,203 |
|---|---|---|---|---|---|---|---|---|
| Equity | 1,223 | 1,360 | 1,407 | 1,512 | 1,500 | 1,518 | 1,544 | 1,570 |
| Borrowings | 799 | 698 | 733 | 623 | 776 | 771 | 651 | 664 |
| Other Non- Current Liabilities | - | - | - | - | 4 | 6 | 5 | 2 |
| Current Liabilities | 946 | 916 | 1,062 | 1,113 | 1,096 | 934 | 1,023 | 967 |
| Total equity and liabilities | 2,968 | 2,974 | 3,202 | 3,248 | 3,376 | 3,229 | 3,223 | 3,203 |
INR in Millions
| Particular | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
| Property, plant and equipment including Capital work-in-progress | 977 | 1,072 | 1,122 | 1,052 |
| Intangible assets including Intangible assets under development | 47 | 69 | 87 | 84 |
| Other Non-Current Assets | 229 | 195 | 257 | 237 |
| Current Assets | 1,721 | 1,912 | 1,763 | 1,830 |
| Total assets | 2,974 | 3,248 | 3,229 | 3,203 |
|---|---|---|---|---|
| Equity | 1,360 | 1,512 | 1,518 | 1,570 |
| Borrowings | 698 | 623 | 771 | 664 |
| Other Non- Current Liabilities | - | - | 6 | 2 |
| Current Liabilities | 916 | 1,113 | 934 | 967 |
| Total equity and liabilities | 2,974 | 3,248 | 3,229 | 3,203 |
INR in Millions
